The Use of an Improved Intragastric Balloon Technique to Reduce Weight in Pre-obese Patients—Preliminary Results

Carvalho, Gustavo; Barros, Cesar Borges; Moraes, Carlos Eduardo Ferreira de; Okazaki, Masaichi; Ferreira, Moacir de Novaes Lima; Silva, José Sergio N.; Albuquerque, Pedro Paulo C. de; Coelho, Raphael de Macedo Cavalcanti

doi:10.1007/s11695-009-9947-y

Cited by 18 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We emphasize, however, that treatment with IGB should not be considered solely for aesthetic reasons. 12 For those patients who had lost >10% of their initial weight, we observed that there was a statistically significant difference in the reduction in the central obesity (VF) that is considered harmful to health because it is more commonly associated with cardiovascular morbidity and mortality.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of Subcutaneous and Visceral Fat After Gastric Balloon Treatment

Lc¹,

Gl²,

Jp³

et al. 2015

JSLS

View full text Add to dashboard Cite

Background and Objectives:This project is a continuation of a larger project entitled “Treatment with intragastric balloon (IGB) in patients with overweight and obesity in Recife” developed by Professor Dr. Gustavo Lopes de Carvalho. It is a project studying the effectiveness of treatment with IGB evaluating the loss of weight and body mass index and its impact on blood pressure, blood glucose, triglycerides, total cholesterol and fractions. It also assesses the lifestyle of patients studying whether treatment with IGB interferes in smoking, alcohol consumption, eating habits and physical exercises performed by patients.The present study added a larger project, the separate evaluation of the different types of abdominal fat—visceral fat and subcutaneous cell tissue fat — and was conducted to discover which of the 2 types of fat undergoes the greater reduction after IGB treatment. To measure these 2 types of fat, we used the ultrasonography technique, because it has been shown to be accurate and noninvasive.Methods:Twenty-five patients were evaluated before and after 6 months of IGB treatment.Results:The patients' ages ranged from 20 to 61 years, with 60% being 40 years of age or older. The majority (72%) were women. All variables (weight, body mass index [BMI], VF, and SCTF) showed a significant reduction (P < .05) in mean values after treatment. The difference was highest in the SCTF (17.5%) and ranged from an 11.4% to an 11.6% reduction in all other variables. The average loss of SCTF was highest among the patients who had lost up to 10.0% of their initial weight (19.2% for the ≤10.0% group vs 15.9% for the >10.0% group); however, the difference was not significant (P = .66). The average loss of VF was higher in the subgroup of patients who had lost >10.0% of their initial weight (16.2% vs 6.3%; P = .003). The Pearson correlation between the reductions in SCTF vs VF was negative, low, and nonsignificant (−0.17; P = .41).Conclusions:After 6 months of IGB treatment, there was no significant difference between the reduction in abdominal SCTF and VF, but the results signify a possible correlation between the percentage of body weight loss and the type of abdominal fat reduced, as the impact on the VF was higher when the patients lost >10.0% of their initial weight.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Fixed volumes of iopamidol contrast (20 mL; Iopamiron; Bracco Imaging, France SAS, Courcouronnes, France) and 2% methylene blue (10 mL) are added, with an approximate final proportion of 65:2:1. 12 …”

Section: Methodsmentioning

confidence: 99%

Analysis of Subcutaneous and Visceral Fat After Gastric Balloon Treatment

Lc¹,

Gl²,

Jp³

et al. 2015

JSLS

View full text Add to dashboard Cite

show abstract

“…20 A follow-up study from the same center including 16 patients with a follow-up of 5-6 months showed significant weight loss with the Silimed gastric balloon. 21 Semistationary antral balloon. The semistationary antral balloon ( JP Industria Farmaceutica, Ribeirao Preto, Brazil) is a small, pear-sized and -shaped device (150-180 mL, saline …”

Section: Endoscopic Devices or Procedures In Bariatricsmentioning

confidence: 99%

The Role of Endoscopy in Bariatrics: Past, Present, and Future

Singhal

Duddempudi

et al. 2012

Journal of Laparoendoscopic & Advanced Surgical Techniques

View full text Add to dashboard Cite

The exponential increase in the rate of obesity and its associated co-morbidities has increased the demand for bariatric surgery. Over the past few decades, surgical weight reduction by gastric restriction, malabsorption, or a combination of both has been the preferred approach to achieve sustained weight loss in the morbidly obese. Although extremely effective, surgical procedures carry significant complications and risk with mortality rates of 1%. Because of the cost, surgical risk, and complications, there is a demand for less invasive procedures. Endoscopic approaches include placement of endoluminal space-occupying devices, stapling devices to reduce gastric volume, barrier devices to reduce small bowel absorptive area, and methods to regulate gastric emptying. Current and ongoing studies have delivered promising results across many aspects of endoscopic approaches. However, many technical obstacles still exist that have to be resolved with further research before endoscopic bariatrics can be widely deployed. At present the role of endoscopy is well established in preoperative evaluation as well as in recognition and management of many postoperative complications in bariatrics. In this article, we review the current and future endoscopic methods for weight reduction that are either in practice or in testing.

show abstract

“… 10 – 12 IGB safety and effectiveness are well established in the treatment of obesity, as documented in many retrospective studies, prospective clinical trials, and, recently, 2 systematic reviews and meta-analyses. 11 – 18 …”

Section: Introductionmentioning

confidence: 99%

“… 3 , 16 , 19 – 21 However, its safety, effectiveness, and value in overweight individuals have not been well studied. 18 , 19 An IRB-approved, prospective study was undertaken to help determine the results of the IGB in overweight adults and to compare these results with those in a simultaneously studied group of obese patients.…”

Section: Introductionmentioning

confidence: 99%

Intragastric Balloon for Overweight Patients

et al. 2016

JSLS

Self Cite

View full text Add to dashboard Cite

Background and Objectives:Current treatments for overweight adults include reduced-calorie diet, exercise, behavior modification, and selective use of medications. Many achieve suboptimal results with these measures and progress to obesity. Whether the intragastric balloon (IGB), a reversible device approved for treatment of obesity, is a safe and effective option in overweight adults is less well studied. We conducted a study to prospectively analyze the safety and effectiveness of IGB in overweight adults, to compare the results to a simultaneously studied cohort of obese patients, and to share procedural tips for safe IGB placement and removal.Methods:One hundred thirty-nine patients were evaluated in this prospective, nonrandomized study. Twenty-six overweight [body mass index (BMI), 26–30)] and 113 obese (BMI > 30) patients underwent outpatient, endoscopic IGB placement under intravenous sedation. The IGB was filled with a 550–900 mL (average, 640 mL) solution of saline, radiological contrast, and methylene blue, with an approximate final proportion of 65:2:1. The patients were followed up at 1–2 weeks and then monthly for 6 months. At 6 months, they underwent IGB removal via an esophageal overtube to optimize safety, and then they were observed for 6 more months.Results:IGB time was 190 ± 36 d in the overweight patients and 192 ± 43 d in the obese patients. Symptoms of IGB intolerance included nausea and pain, which were transiently present in 50–95% of patients for several days, and necessitated early IGB removal in 6% of patients. There were no procedure-related complications and no IGB-related esophagitis, erosion, perforation, or obstruction. The percentage of excess weight loss (EWL%) was 96 ± 54% in the overweight group and 41 ± 26% in the obese group (P < 0.001).Conclusion:In overweight adults failing standard treatments, IGB placement for 6 months had an acceptable safety profile and excellent weight loss.

show abstract

The Use of an Improved Intragastric Balloon Technique to Reduce Weight in Pre-obese Patients—Preliminary Results

Cited by 18 publications

References 9 publications

Analysis of Subcutaneous and Visceral Fat After Gastric Balloon Treatment

Analysis of Subcutaneous and Visceral Fat After Gastric Balloon Treatment

The Role of Endoscopy in Bariatrics: Past, Present, and Future

Intragastric Balloon for Overweight Patients

Contact Info

Product

Resources

About